Figure 1: Incidence of Age-Standardized Incident Rates for Cancer Globally, 2020
Figure 2: Relative Percent of New Lymphomas Expected in U.S. in 2020
Figure 3: Prevalence of Different Hematological Malignancies Across U.S. (2013-2017)
Figure 4: Impact Analysis on the Global Minimal Residual Disease Testing Market
Figure 5: Global MRD Testing Market (by Application), $Million, 2019 vs. 2025
Figure 6: Global MRD Testing Market (by Hematological Malignancy), $Million, 2019 vs. 2025
Figure 7: Global Minimal Residual Disease Testing Market (by Technology), $Million, 2019 vs. 2025
Figure 8: Global Minimal Residual Disease Testing Market (by End User), $Million, 2019 vs. 2025
Figure 9: Global Minimal Residual Disease Testing Market Snapshot
Figure 1.1: Global MRD Testing Market Segments
Figure 2.1: Bottom-Up Approach (Segment-Wise Analysis)
Figure 2.2: Top-Down Approach (Segment-Wise Analysis)
Figure 3.1: Global MRD Testing Market, $Million, 2018-2025
Figure 3.2: Global MRD Testing Market Potential, $Million, 2019-2025
Figure 4.1: Global Incidence and Mortality Rate for Individual Hematological Conditions (2016)
Figure 4.2: Estimated New Cases of Hematological Cancer, 2020
Figure 5.3: Laboratory Methods for MRD Detection
Figure 5.4: Classification on In-Vitro Diagnostics in India
Figure 5.5: Methods to Achieve Coverage
Figure 5.6: Supply Chain Analysis of Laboratory Developed Tests
Figure 5.7: Supply Chain Analysis of In-Vitro Diagnostics
Figure 6.1: Share of Key Developments and Strategies, January 2018-December 2020
Figure 6.2: Synergistic Activities Share (by Company), January 2018-December 2020
Figure 6.3: Market Share Analysis for Global MRD Testing Market, 2018 and 2019
Figure 6.4: Growth Share Analysis for Global MRD Testing Market (by Company), 2019
Figure 6.5: Growth Share Analysis for Global MRD Testing Market (by Technology), 2019-2025
Figure 6.6: Growth Share Analysis for Global MRD Testing Market (by Application), 2019-2025
Figure 6.7: Growth Share Analysis for Global MRD Testing Market (by End User), 2019-2025
Figure 7.1: Global Minimal Residual Disease Testing Market (by Technology), $Million, 2019-2025
Figure 7.2: Global Minimal Residual Disease Testing Market (by Flow Cytometry), $Million, 2019-2025
Figure 7.3: Global Minimal Residual Disease Testing Market (PCR), $Million, 2019-2025
Figure 7.4: Global Minimal Residual Disease Testing Market (NGS), $Million, 2019-2025
Figure 7.5: Global Minimal Residual Disease Testing Market (Other Technologies), $Million, 2019-2025
Figure 8.1: Global MRD Testing Market (by Application)
Figure 8.2: Global MRD Testing Market (by Application), 2019-2025
Figure 8.3: Global MRD Testing Market (by Hematological Malignancies), 2019 vs. 2025
Figure 8.4: Global Minimal Residual Disease Testing Market (Non-Hodgkin’s Lymphoma), $Million, 2019-2025
Figure 8.5: Global Minimal Residual Disease Testing Market (by Non-Hodgkin’s Lymphoma Type), $Million, 2019-2025
Figure 8.6: Global NHL MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.7: Global Minimal Residual Disease Testing Market (Multiple Myeloma), $Million, 2019-2025
Figure 8.8: Global MM-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.9: Global Minimal Residual Disease Testing Market (Acute Lymphoblastic Leukemia), $Million, 2019-2025
Figure 8.10: Global ALL-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.11: Global Minimal Residual Disease Testing Market (Chronic Lymphocytic Leukemia), $Million, 2019-2025
Figure 8.12: Global CLL-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.13: Global Minimal Residual Disease Testing Market (Acute Myeloid Leukemia), $Million, 2019-2025
Figure 8.14: Global AML-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.15: Global Minimal Residual Disease Testing Market (Chronic Myeloid Leukemia), $Million, 2019-2025
Figure 8.16: Global CML-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.17: Global Minimal Residual Disease Testing Market (Hodgkin’s Lymphoma), $Million, 2019-2025
Figure 8.18: Global HL-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.19: Global Minimal Residual Disease Testing Market (Other Leukemia), $Million, 2019-2025
Figure 9.1: Global Minimal Residual Disease Testing Market (by End User), $Million, 2019-2025
Figure 9.2: Specialty Clinics and Hospitals Market, $Million, 2019-2025
Figure 9.3: Diagnostic Laboratories Market, $Million, 2019-2025
Figure 9.4: Research Institutions Market, $Million, 2019-2025
Figure 9.5: Global Minimal Residual Disease Testing Market (Other End Users), $Million, 2019-2025
Figure 10.1: Global Minimal Residual Disease Testing Market (by Region), $Million, 2019 and 2025
Figure 10.2: North America: Market Dynamics
Figure 10.3: North America Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.4: North America Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
Figure 10.5: U.S. Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.6: U.S. Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.7: Growth-Share Analysis for U.S. Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.8: Canada Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.9: Canada Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.10: Growth-Share Analysis for Canada Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.11: Europe: Market Dynamics
Figure 10.12: Europe Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.13: Europe Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
Figure 10.14: Germany Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.15: Germany Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.16: Growth-Share Analysis for Germany Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.17: Italy Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.18: Italy Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.19: Growth-Share Analysis for Italy Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.20: France Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.21: France Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.22: Growth-Share Analysis for France Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.23: U.K. Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.24: U.K. Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.25: Growth-Share Analysis for U.K. Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.26: Spain Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.27: Spain Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.28: Growth-Share Analysis for Spain Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.29: Rest-of-Europe Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.30: Rest-of-Europe Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.31: Growth-Share Analysis for Rest-of-Europe Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.32: Asia-Pacific: Market Dynamics
Figure 10.33: Asia-Pacific Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.34: Asia-Pacific Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
Figure 10.35: China Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.36: China Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.37: Growth-Share Analysis for China Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.38: India Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.39: India Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.40: Growth-Share Analysis for India Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.41: Japan Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.42: Japan Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.43: Growth-Share Analysis for Japan Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.44: South Korea Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.45: South Korea Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.46: Growth Share Analysis for South Korea MRD Testing Market (by Application), 2019-2025
Figure 10.47: Australia Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.48: Australia Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.49: Growth-Share Analysis for Australia Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.50: Number of Death in Australia by Leukemia (2012-2017)
Figure 10.51: Singapore Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.52: Singapore Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.53: Growth-Share Analysis for Singapore Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.54: Rest-of-APAC Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.55: Rest-of-APAC Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.56: Growth-Share Analysis for Rest-of-APAC Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.57: Latin America: Market Dynamics
Figure 10.58: Latin America and Middle East Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.59: Latin America and Middle East Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
Figure 10.60: Brazil Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.61: Brazil Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.62: Growth-Share Analysis for Brazil Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.63: Mexico Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.64: Mexico Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.65: Growth-Share Analysis for Mexico Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.66: Saudi Arabia Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.67: Saudi Arabia Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.68: Growth-Share Analysis for Saudi Arabia Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.69: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.70: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.71: Growth-Share Analysis for Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.72: Rest-of-the-World Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.73: Rest-of-the-World Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.74: Growth-Share Analysis for Rest-of-the-World Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 11.1: ICON plc: Overall Product Portfolio
Figure 11.2: ICON plc: Overall Financials, 2017-2019
Figure 11.3: ICON plc: Revenue (by Region), 2017-2019
Figure 11.5: ArcherDX, Inc.: Portfolio
Figure 11.6: ArcherDX, Inc.: SWOT Analysis
Figure 11.7: ARUP Laboratories: Product Portfolio
Figure 11.8: ARUP Laboratories: SWOT Analysis
Figure 11.9: ASURAGEN INC.: Product Portfolio
Figure 11.10: ASURAGEN INC.: SWOT Analysis
Figure 11.11: Cergentis B.V.: Product Portfolio
Figure 11.12: Cergentis B.V.: SWOT Analysis
Figure 11.13: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 11.14: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 11.15: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 11.16: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 11.17: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 11.18: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 11.19: Mission Bio, Inc.: Product Portfolio
Figure 11.20: Mission Bio, Inc.: SWOT Analysis
Figure 11.21: Guardant Health: Portfolio
Figure 11.22: Guardant Health: Overall Financials, 2017-2019
Figure 11.23: Guardant Health: Revenue (by Segment), 2017-2019
Figure 11.24: Guardant Health: Revenue (by Region), 2017-2019
Figure 11.25: Guardant Health: SWOT Analysis
Figure 11.26: Invivoscribe, Inc.: Product Portfolio
Figure 11.27: Invivoscribe, Inc.: SWOT Analysis
Figure 11.28: Laboratory Corporation of America Holdings: Product Portfolio
Figure 11.29: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 11.30: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 11.31: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 11.32: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 11.33: Inivata Ltd.: Product Portfolio
Figure 11.34: Inivata Ltd.: SWOT Analysis
Figure 11.35: Natera, Inc.: Portfolio
Figure 11.36: Natera, Inc.: Overall Financials, 2017-2019
Figure 11.37: Natera, Inc.: Revenue (by Segment), 2017-2019
Figure 11.38: Natera, Inc.: R&D Expenditure, 2017-2019
Figure 11.39: Natera, Inc.: SWOT Analysis
Figure 11.40: NeoGenomics Laboratories, Inc.: Portfolio
Figure 11.41: NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019
Figure 11.42: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 11.43: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 11.44: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 11.45: Opko Health: Portfolio
Figure 11.46: Opko Health, Inc.: Overall Financials, 2017-2019
Figure 11.47: Opko Health, Inc.: Revenue (by Segment), 2017-2019
Figure 11.48: Opko Health, Inc.: Revenue (by Region), 2017-2019
Figure 11.49: Opko Health, Inc.: R&D Expenditure, 2017-2019
Figure 11.50: Opko Health, Inc.: SWOT Analysis
Figure 11.51: Quest Diagnostics Incorporated: Product Portfolio
Figure 11.52: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 11.53: Quest Diagnostics Incorporated: SWOT Analysis
Figure 11.54: Sysmex Corporation: Product Portfolio
Figure 11.55: Sysmex Corporation: Overall Financials, 2017-2019
Figure 11.56: Sysmex Corporation: Revenue (by Business Segment), 2018-2019
Figure 11.57: Sysmex Corporation R&D Expenditure, 2017-2019
Figure 11.58: Sysmex Corporation: SWOT Analysis
Figure 11.59: Adaptive Biotechnologies Corporation: Product Portfolio
Figure 11.60: Adaptive Biotechnologies Corporation: Overall Financials, 2017-2019
Figure 11.61: Adaptive Biotechnologies Corporation: Revenue (by Business Segment), 2017-2019
Figure 11.62: Adaptive Biotechnologies Corporation R&D Expenditure, 2017-2019
Figure 11.63: Adaptive Biotechnologies Corporation: SWOT Analysis